참고문헌
- Brennan SK, Matsui W (2009). Cancer stem cells: controversies in multiple myeloma. J Mol Med (Berl), 87, 1079-85. https://doi.org/10.1007/s00109-009-0531-7
- Chiron D, Surget S, Maiga S, et al (2012). The peripheral CD138+ population but not the CD138-population contains myeloma clonogenic cells in plasma cell leukaemia patients. Br J Haematol, 156, 679-83. https://doi.org/10.1111/j.1365-2141.2011.08904.x
- Hong D, Chen HX, Yu HQ, et al (2011). Quantitative proteomic analysis of dexamethasone-induced effects on osteoblast differentiation, proliferation, and apoptosis in MC3T3-E1 cells using SILAC. Osteoporos Int, 22, 2175-86. https://doi.org/10.1007/s00198-010-1434-8
- Hosen N, Matsuoka Y, Kishida S, et al (2012). CD138-negative clonogenic cells are plasma cells but not B cells in some multiple myeloma patients. Leukemia, 26, 2135-41. https://doi.org/10.1038/leu.2012.80
- Huff CA, Matsui W (2008). Multiple myeloma cancer stem cells. J Clin Oncol, 26, 2895-900. https://doi.org/10.1200/JCO.2007.15.8428
- Jakubikova J, Adamia S, Kost-Alimova M, et al (2011). Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications. Blood, 117, 4409-19. https://doi.org/10.1182/blood-2010-02-267344
- Khan MM, Mori M, Sakauchi F, et al (2006). Risk factors for multiple myeloma: evidence from the Japan Collaborative Cohort (JACC) study. Asian Pac J Cancer Prev, 7, 575-81.
- Kyle RA, Gertz MA, Witzig TE, et al (2003). Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc, 78, 21-33. https://doi.org/10.4065/78.1.21
- Kyle RA, Rajkumar SV(2008). Multiple myeloma. Blood, 111, 2962-72. https://doi.org/10.1182/blood-2007-10-078022
- Matsui W, Huff CA, Wang Q, et al (2004). Characterization of clonogenic multiple myeloma cells. Blood, 103, 2332-6. https://doi.org/10.1182/blood-2003-09-3064
- Matsui W, Wang Q, Barber JP, et al (2008). Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res, 68, 190-7. https://doi.org/10.1158/0008-5472.CAN-07-3096
- Paino T, Ocio EM, Paiva B, et al (2012). CD20 positive cells are undetectable in the majority of multiple myeloma cell lines and are not associated with a cancer stem cell phenotype. Haematologica, 97, 1110-4. https://doi.org/10.3324/haematol.2011.057372
- Pilarski LM, Hipperson G, Seeberger K, et al (2000). Myeloma progenitors in the blood of patients with aggressive or minimal disease: engraftment and self-renewal of primary human myeloma in the bone marrow of NOD SCID mice. Blood, 95, 1056-65.
- Pilarski LM, Seeberger K, Coupland RW, et al (2002). Leukemic B cells clonally identical to myeloma plasma cells are myelomagenic in NOD/SCID mice. Exp Hematol, 30, 221-8. https://doi.org/10.1016/S0301-472X(01)00788-3
- Raab MS, Podar K, Breitkreutz I, et al (2009). Multiple myeloma. Lancet, 374, 324-39. https://doi.org/10.1016/S0140-6736(09)60221-X
- Rajkumar SV (2011). Multiple myeloma: (2011) update on diagnosis, risk-stratification, and management. Am J Hematol, 86, 57-65. https://doi.org/10.1002/ajh.21913
- Yaccoby S, Barlogie B, Epstein J (1998). Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations. Blood, 92, 2908-13.
- Yaccoby S, Epstein J (1999). The proliferative potential of myeloma plasma cells manifest in the SCID-hu host. Blood, 94, 3576-82.
- Zhang Z, Zhang L, Hua Y, et al (2010). Comparative proteomic analysis of plasma membrane proteins between human osteosarcoma and normal osteoblastic cell lines. BMC Cancer, 10, 206-14. https://doi.org/10.1186/1471-2407-10-206